Mar. 26 at 12:33 PM
$ABBV Third Time's a Charm?
- Successfully navigated the loss of exclusivity (LOE) of its blockbuster drug, Humira, which once generated more than 50% of its total revenues.
- 2026,
$ABBV expects combined Skyrizi and Rinvoq sales of more than
$31 billion, which is
$0.5 billion more than its 2027 long-term guidance of
$31 billion.
- AbbVie has been on an acquisition spree in the past couple of years to bolster the early-stage pipeline that should drive long-term growth. Particularly, it is signing several M&A deals in the immunology space, its core area, and also inking some early-stage deals in oncology and neuroscience areas
